On the eve of the first session of the 15th CPPCC Chengdu Committee, in order to optimize the group speech materials titled "Offering advice and suggestions for the development of new economy", on January 25, 2018, Gan Huatian, Co-chairman of Chinese Peasants and Workers Democratic Party Chengdu Committee, led a delegation to inspect Chengdu's health care industry. Hu Weifeng, Vice Chairman of Chinese Peasants and Workers Democratic Party Chengdu Committee, accompanied him in the inspection.

In the morning, Gan Huatian and his delegation inspected Chengdu Medical City in Wenjiang District. In Project Planning Hall, Duan Meihua, Deputy Director of Chengdu Medical City (Science Park) and Head of the Investment Promotion Department, briefed the inspection group on the basic information of Chengdu Medical City. According to him, Chengdu People's Government approved the construction of Chengdu Medical City in Wenjiang District in 2008; Covering an area of some 30 square kilometers, Chengdu Medical City follows a concept of integrating medicine science, medical care, and medicine to push for the fast growth of biomedicine industrial cluster, and promote the development, fruit transformation, and industrialization of biomedicine technology, seeking to shape a powerhouse of biomedicine manufacturing in central and western China. According to the plan, by 2020, Chengdu Medical City will shape 3-4 biomedicine industrial clusters with well-established industrial chains, realizing output of RMB 75 billion in the total biomedicine industry; by 2025, the output of the total biomedicine industry will top RMB 200 billion. Afterwards, the inspection group inspected the CMC Innovation Center in Chengdu Medical City. Afterwards, they held a seminar with Chengdu Medical City (Science Park). At the meeting, the inspection group heard reports on the construction, management, operation and development of Chengdu Medical City. Deputy Director Duan Meihua also talked about the problems and difficulties in present works. Chengdu Medical City is designed to realize the integration of medicine science, medical care, and medicine, covering smart medicine, precision medicine, medical R&D, medical equipment, innovative traditional Chinese medicine, biomedicine, health care insurance, and other fields, with distinctive advantages and a promising future, noted Co-chairman Gan Huatian. The settling down of major professional medical institutions has brought high-end medical technology and advanced medical instrument and equipment to Chengdu, which will enhance the quality of medical care in Chengdu and even central and western China; the settling down of various R&D centers will produce more medical results and more advanced medical methods to tackle more difficult and complicated diseases and relieve more patients from the pain of diseases; with the influx of various industrial elites to Chengdu Medical City, their cooperation and communication with local medical workers will upgrade the whole quality of Chengdu's medical services. Today's inspection features rich contents, and is very rewarding. We will comb through relevant contents and questions in the inspection, offer more advice and suggestions, and contribute the wisdom and power of Chinese Peasants and Workers Democratic Party to the development of Chengdu Medical City. Vice Chairman Hu Weifeng briefed on Chengdu Committee's inspection on health care industry

In the afternoon, the delegation inspected Chengdu HitGen in Tianfu Life Science Park, Chengdu Hi-tech Zone. First, the responsible person of Chengdu HitGen briefed on corporate profile. Chengdu HitGen is a biotechnology firm built by Dr. Li Jin in 2012, dedicated to new drug R&D. Dr. Li was previously Global Scientific Director of Compounds at AstraZeneca. Owning "DNA Encoded Compound Library" synthesis and screening techniques, which are independent intellectual property rights, Chengdu HitGen is committed to clearing away technical barriers for the discovery of lead compound in developing innovative drugs, so as to speed up R&D process, reduce cycle and costs, and serve as the source power for China's small molecule drug R&D. Afterwards, the inspection group inspected the laboratory, R&D center, production center, and sales center of the company. Chengdu HitGen has been recognized both at home and abroad for its core drug-making technology and new drug discovery capability; the company boasts a strong pool of some 200 talents with global vision and innovation capacity, and those with doctoral degree account for 20% of total R&D staff and over half of them have worked with famous research institutes; Chengdu HitGen will be bound to make new contributions for Chengdu's biomedicine industry, said Co-chairman Gan Huatian. Going forward, the Chengdu Committee will make further investigation and research in this field, fulfill its duties of participating in the administration and discussion of regional affairs, in a way to promote the sound development of Chengdu's health care industry.